Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice.

Drug Des Devel Ther · 2015 · PMC4572747 · PMID 26392754

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendP =0.06so close (0.05 < p ≤ 0.1)

Thickness of fibrous caps Microscopic evaluation in 28-week-old mice showed a trend towards thicker fibrous caps in mice treated with dabigatran etexilate compared to controls (25±2 μm versus 19±2 μm, P =0.06) ( Figure 2B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.